Personalis EPS - Earnings per Share 2018-2024 | PSNL
Personalis eps - earnings per share from 2018 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Personalis Annual EPS |
| 2023 |
$-2.25 |
| 2022 |
$-2.48 |
| 2021 |
$-1.49 |
| 2020 |
$-1.20 |
| 2019 |
$-1.39 |
| 2018 |
$-6.49 |
| 2017 |
$-7.78 |
| Personalis Quarterly EPS |
| 2024-09-30 |
$-0.64 |
| 2024-06-30 |
$-0.24 |
| 2024-03-31 |
$-0.26 |
| 2023-12-31 |
$-0.54 |
| 2023-09-30 |
$-0.60 |
| 2023-06-30 |
$-0.50 |
| 2023-03-31 |
$-0.61 |
| 2022-12-31 |
$-0.67 |
| 2022-09-30 |
$-0.58 |
| 2022-06-30 |
$-0.60 |
| 2022-03-31 |
$-0.63 |
| 2021-12-31 |
$-0.46 |
| 2021-09-30 |
$-0.40 |
| 2021-06-30 |
$-0.34 |
| 2021-03-31 |
$-0.29 |
| 2020-12-31 |
$-0.35 |
| 2020-09-30 |
$-0.27 |
| 2020-06-30 |
$-0.29 |
| 2020-03-31 |
$-0.29 |
| 2019-12-31 |
$1.56 |
| 2019-09-30 |
$-0.22 |
| 2019-06-30 |
$-0.89 |
| 2019-03-31 |
$-1.84 |
| 2018-12-31 |
$0.00 |
| 2018-09-30 |
$-1.19 |
| 2018-06-30 |
$-2.39 |
| 2017-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.412B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
